Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: GlobeNewswire
WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has successfully reached its target of 20 activated clinical trial sites in the Phase 2b portion of the VOICE trial. Validive® is a small, easy-to-use mucobuccal tablet that can be self-administered in the patient’s home setting. The VOICE study evaluates Validive® for the prevention of severe oral mucositis (SOM) in oropharyngeal cancer patients. SOM results from the chemoradiation used to treat oropharyngeal cancer (OPC). There is no FDA-approved preventative or treatment option for the estimated 40,000 OPC patients in the US annually who are at-risk of developing SOM. “We are very pleased to reach this clinical milestone and to achieve clinical site enrollment rates that have exceeded our bas
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingGlobeNewswire
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings [Yahoo! Finance]Yahoo! Finance
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsGlobeNewswire
- Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Jonestrading from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.MarketBeat
MNPR
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form 8-K
- 4/2/24 - Form 4
- MNPR's page on the SEC website